Integra LifeSciences, AlloSource to Market HuMend

Integra LifeSciences has entered into an agreement with nonprofit cellular and tissue network AlloSource to market the HuMend acellular dermal matrix.

Under the agreement, Integra gains access and right to market the acellular matrices, which originate from donated human dermis. The expansion of its product line allows Integra to provide soft tissue repair for patients undergoing plastic reconstructive procedures.

Integra is scheduled to launch HuMend ADM mid-year. — Anisa Jibrell